These findings highlight the potency of STEAP1-mBBζ CAR T cells in eradicating STEAP1+ prostate cancer and further suggest that adjunct therapeutic strategies may be needed to overcome resistance in subgroups of advanced prostate cancer patients where heterogeneity of STEAP1 expression is present (Fig. 1e). The gene discussed is STEAP1; the disease is Familial prostate cancer.